See more : Zoom2u Technologies Limited (Z2U.AX) Income Statement Analysis – Financial Results
Complete financial analysis of ChemoCentryx, Inc. (CCXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ChemoCentryx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Aris Water Solutions, Inc. (ARIS) Income Statement Analysis – Financial Results
- Gensol Engineering Limited (GENSOL.BO) Income Statement Analysis – Financial Results
- Bebuzee Inc. (BBUZ) Income Statement Analysis – Financial Results
- GasLog Ltd. (GLOG-PA) Income Statement Analysis – Financial Results
- Huntington Bancshares Incorporated (HBANM) Income Statement Analysis – Financial Results
ChemoCentryx, Inc. (CCXI)
About ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.22M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Cost of Revenue | 302.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 31.92M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Gross Profit Ratio | 99.06% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 82.99M | 77.88M | 70.28M | 62.74M | 49.50M | 37.95M | 33.18M | 33.82M | 33.54M | 34.57M | 28.36M | 33.53M | 27.47M | 35.06M |
| General & Administrative | 0.00 | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.85M | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Other Expenses | 302.00K | 0.00 | -176.00K | 0.00 | 0.00 | -500.00K | 0.00 | 0.00 | 27.48M | 29.15M | 0.00 | 0.00 | 0.00 | -536.00K |
| Operating Expenses | 162.14M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Cost & Expenses | 162.45M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Interest Income | 859.00K | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 402.00K | 436.00K | 297.00K | 1.76M |
| Interest Expense | -2.70M | 2.64M | 2.15M | 1.22M | 4.00K | 0.00 | 0.00 | 24.00K | 59.00K | 794.00K | 734.00K | 81.00K | 76.00K | 129.00K |
| Depreciation & Amortization | 3.14M | 797.00K | 1.64M | 512.00K | 418.00K | 348.00K | 477.00K | 543.00K | 576.00K | 592.00K | 754.00K | 660.00K | 713.00K | 707.00K |
| EBITDA | -131.31M | -51.92M | -51.70M | -36.23M | 18.28M | -39.62M | -46.83M | -46.36M | -38.04M | -38.51M | -3.13M | -2.43M | 16.71M | -17.66M |
| EBITDA Ratio | -407.49% | -80.00% | -143.80% | -84.50% | 22.16% | -346.44% | 0.00% | 0.00% | -627.69% | -710.56% | -9.88% | -6.96% | 33.58% | -74.97% |
| Operating Income | -134.45M | -55.18M | -58.30M | -40.27M | 16.49M | -40.72M | -47.69M | -47.40M | -39.12M | -39.63M | -4.30M | -5.96M | 15.70M | -20.13M |
| Operating Income Ratio | -417.24% | -85.03% | -162.17% | -93.92% | 19.99% | -356.10% | 0.00% | 0.00% | -645.46% | -731.32% | -13.58% | -17.09% | 31.55% | -85.46% |
| Total Other Income/Expenses | -1.84M | -179.00K | 2.81M | 2.30M | 1.37M | 757.00K | 384.00K | 470.00K | 442.00K | -261.00K | -316.00K | 2.79M | 221.00K | 1.63M |
| Income Before Tax | -131.76M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.17M | 15.92M | -18.49M |
| Income Before Tax Ratio | -408.87% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -9.09% | 32.00% | -78.52% |
| Income Tax Expense | -2.70M | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 418.00K | -73.00K | 293.00K | -23.00K |
| Net Income | -129.06M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.10M | 15.62M | -18.47M |
| Net Income Ratio | -400.51% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -8.88% | 31.41% | -78.43% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 | 0.37 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 | 0.36 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| Weighted Avg Shares Out | 65.69M | 65.69M | 56.90M | 49.81M | 48.41M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
| Weighted Avg Shares Out (Dil) | 65.69M | 65.69M | 56.90M | 49.81M | 49.62M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ChemoCentryx, Inc
Down 30% In A Month, Is There More Pain For ChemoCentryx Stock?
SHAREHOLDER ALERT: Robbins LLP Investigates ChemoCentryx, Inc. (CCXI) on Behalf of Shareholders
ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis
Why ChemoCentryx Shares Are Rising
ChemoCentryx's Avacopan Scores European Approval For ANCA-Associated Vasculitis
Source: https://incomestatements.info
Category: Stock Reports